UK MHRA approves Pfizer/BioNTech’s Comirnaty JN.1 Covid-19 vaccine for children from infancy and adults

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new version of the Pfizer/BioNTech Covid-19 vaccine, Comirnaty, targeting the JN.1 Covid-19 subvariant. This vaccine prompts the immune system to produce antibodies and blood cells to combat Covid-19.

Four versions of the Comirnaty JN.1 vaccine were approved under the International Recognition Procedure, confirming their safety, quality, and effectiveness. The MHRA will continue to monitor the vaccine's safety closely.

Patients can access a list of side effects in the patient information leaflet, available at pharmacies or on the MHRA website. Any side effects should be reported to healthcare professionals or through the Yellow Card scheme to help enhance safety monitoring.

Approved in collaboration with the European Medicines Agency (EMA), the new Comirnaty JN.1 products are updates of the existing vaccine, with specific doses for adults, children, and infants.